Stay updated on Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check27 days agoChange Detected- Revision updated to v3.5.0; previous revision v3.4.3 was removed.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision: v3.4.3 is now displayed on the page, replacing the previous v3.4.2.SummaryDifference0.1%

- Check63 days agoChange DetectedRevision: v3.4.2 was added and the funding-status notice and Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check70 days agoChange DetectedAdded a government funding-status notice and a site update to Revision: v3.4.1 (replacing v3.4.0). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.6%

- Check77 days agoChange DetectedGlossary display was added to the study page, along with a new label 'Last Update Submitted that Met QC Criteria' and a site revision tag 'Revision: v3.4.0'. The prior label 'Last Update Submitted that met QC Criteria', the 'No FEAR Act data' entry, and the older revision tag 'Revision: v3.3.4' were removed.SummaryDifference0.3%

- Check91 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing the previous Revision: v3.3.3.SummaryDifference0.1%

Stay in the know with updates to Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Tucatinib in HER2+ Metastatic Breast Cancer Clinical Trial page.